This week in transparency news: November 21 – December 4, 2020
by Staff Writer
Clinical trial transparency in the pharmaceutical industry is continually evolving, and to stay on top of the news, TrialAssure brings a bi-weekly round-up of some of the key stories. Select recent and relevant stories are as follows.
COVID-19 vaccine registry launched by Mayo to ID those interested in clinical trials – WIZM News Talk
Mayo Clinic has launched a COVID-19 Vaccine Registry for those interested in participating in upcoming COVID-19 vaccine clinical trials. Currently, with more than 150 vaccine candidates in preclinical evaluation and more than 40 in clinical trials worldwide, Mayo Clinic is still accepting names to the registry who may be contacted in the future to determine if they are eligible to participate in a COVID-19 vaccine trial at Mayo Clinic.
Read more on wizmnews.com
How pharma can build trust in COVID-19 vaccines: Transparency on trials and side-effects – The Conversation
Promising results from large clinical trials testing three vaccines to prevent COVID-19 bring us a step closer to a widely available vaccine. Polling in the United States and Canada reveals increasing distrust of COVID-19 vaccines, but as vaccine developers and sponsors of ongoing trials, pharmaceutical companies are uniquely situated to help promote public trust in COVID-19 vaccines.
Read more on TheConversation.com
Research Community Alert – NIH Finalizes Updated Data Sharing Policy – The National Law Review
The National Institutes of Health (NIH) issued its final NIH Policy for Data Management and Sharing (the DMS Policy), which updates and replaces the 2003 NIH Data Sharing Policy. The DMS Policy sets forth a number of standards for good data management practices and data sharing expectations applicable to research funded by NIH.
Read more on The National Law Review